If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
104
results.
Updated on
21/02/2026 [07:16:00]
Results 100 to 104 of 104
Absstract of: US2025387468A1
The invention provides a compound comprising one, two, three or more non-natural HRC sequence of a viral spike peptide conjugated to a hydrophobic moiety via an optional linker. The hydrophobic moiety can be a membrane integrating ligand, such as a cholesterol, a sphingolipid, a glycolipid, a glycerophospholipid. The non-natural viral spike peptide is preferably a coronavirus spike protein characterized by one or more D-amino acids. The peptides of the invention inhibit viral fusion. The invention includes compositions for the delivery of compounds of the invention, such as pulmonary or nasal delivery. The invention also provides a method of treating or preventing a viral infection, including for example a SARS-CoV-2 (COVID-19) infection, in a subject in need thereof comprising administering an effective amount of a compound of the invention.
Absstract of: UA161685U
Method for obtaining 6-benzyl-3-arylamino-4H-1,2,4-triazine-5-ones with predicted activity against the SARS-CoV-2 virus: where R=OCHF2, NHC6H5, whereby equimolar amounts of 6-benzyl-3-methylsulfanil-4H-1,2,4-triazine-5-one and the corresponding substituted aromatic amine are heated in an oil bath at a temperature of 170 °C for two hours in an argon atmosphere; after cooling, the reaction mixture is ground with propanol-2, the crystalline precipitate is filtered off, washed with propanol-2, dried, and purified by crystallization from ethanol.
Absstract of: UA161684U
Method for obtaining 3-(41-chlorobenzyl)-mercapto-6-(4-R-benzyl)-4H-1,2,4-triazine-5-ones with predicted activity against SARS-CoV-2 virus, in which equimolar amounts of 3-mercapto-6 -(4-R-benzyl)-4H-1,2,4-triazine-5-ones and 4-chlorobenzyl chloride are boiled in dry acetonitrile with stirring in the presence of calcined K2CO3 for three hours, after which the reaction mass is cooled, poured into ice water, the precipitate is filtered, dried, and crystallized from propanol-2.
Nº publicación: UA130231C2 24/12/2025
Applicant:
SHIN POONG PHARMACEUTICAL CO LTD [KR]
\u0428\u0406\u041D\u042C \u041F\u0423\u041D\u0413 \u0424\u0410\u0420\u041C\u0410\u0421\u042C\u042E\u0422\u0406\u041A\u0410\u041B \u041A\u041E., \u041B\u0422\u0414.,
\u0428\u0418\u041D\u042C \u041F\u0423\u041D\u0413 \u0424\u0410\u0420\u041C\u0410\u0421\u042C\u042E\u0422\u0418\u041A\u0410\u041B \u041A\u041E., \u041B\u0422\u0414.
Absstract of: UA130231C2
The present invention relates to a use of pyronaridine or a pharmaceutically acceptable salt thereof, and/or artemisinin or a derivative thereof for preventing or treating an epidemic RNA viral infectious disease, and more specifically, to a pharmaceutical composition for preventing or treating an epidemic RNA viral infectious disease, in particular, Coronavirus Disease 2019 (COVID-19), the composition comprising a therapeutically effective amount of pyronaridine or a pharmaceutically acceptable salt thereof, and/or artemisinin or a derivative thereof, together with a pharmaceutically acceptable carrier.
BOPI
Electronic site
